The Burden of Illness of Vasomotor Symptoms Associated with Menopause


Malacan J1, Bolling KR2, Haberland C3, Gaianu L4, Smith N5, Woods M6, Smith M7
1Bayer Consumer Carer AG, Basel, Switzerland, 2Bayer U.S. LLC, Whippany, NJ, USA, 3Bayer AG, Berlin, BE, Germany, 4Bayer Public Limited Company, Reading, UK, 5Lumanity, Cheshire, CHW, UK, 6Lumanity, Sheffield, NYK, UK, 7Lumanity, London, UK

OBJECTIVES: Menopausal transition is characterized by progressive decrease of estrogen levels causing various symptoms. Vasomotor symptoms (VMS; known as hot flashes) are the most common and have a significant impact on affected women. This review synthesizes the humanistic burden, economic burden and current treatment landscape of VMS associated with menopause.

METHODS: A targeted burden of illness review was conducted including searches of MEDLINE®, Embase® and the National Health Service Economic Evaluation Database (NHS EED) to identify studies assessing the burden of VMS associated with menopause. Supplementary grey literature searches provided further evidence.

RESULTS: Of 6,614 records identified, 276 studies were included into this review. Menopause affects 1 billion women worldwide. Approximately 80% of menopausal women experience VMS, with around 46% overall experiencing moderate-to-severe symptoms, lasting for up to 10 years. 24% of women with VMS reported that symptoms have a substantial impact on their quality of life (QoL), increasing with greater severity (mild: 11%; moderate: 27%; severe: 52%). More than 50% of women with VMS reported that VMS impacted their sleep, subsequently affecting their ability to perform daily tasks and work productivity. Furthermore, a greater severity of VMS has been associated with a marked increase in work impairment (mild or moderate: 4–14%; severe: 25–26%). Currently there are limited treatment options for menopausal symptoms, including VMS, with approximately 36% of women reporting dissatisfaction with their level of VMS control. Hormone therapy may not be suitable for all women, with 53–68% of women who are eligible for hormone therapy being averse to using it.

CONCLUSIONS: VMS associated with menopause can be severe and have a detrimental impact on QoL and work/productivity. Despite this, there are limited effective treatment options and a significant percentage of women are unable or unwilling to use current therapy, highlighting the considerable unmet need.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)




Economic Evaluation, Patient-Centered Research, Study Approaches

Topic Subcategory

Literature Review & Synthesis, Patient-reported Outcomes & Quality of Life Outcomes, Work & Home Productivity - Indirect Costs


No Additional Disease & Conditions/Specialized Treatment Areas, Reproductive & Sexual Health

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now